Replies to post #119799 on Biotech Values

[zipjet]

"Continues" certainly does not apply to the most recent quarter.

Given the big jump in pricing of MS drugs, and the greater influence of patient and physician, I suspect there would be a much higher demand elasticity that could be utilized by mC pricing at a bigger discount than mL. Call it -22%. And watch TEVA squirm.

ij

[jbog]

Dew,

It would have been intersting to keep track of the product pricing because it looks like Copaxones growth is just a result of their pricing.